EGFR and lung adenocarcinoma: The incidence of lung adenocarcinoma has increased significantly over the past 20 years, especially among females.[31] The third‐generation EGFR‐TKI AZD9291 has significantly improved survival, reaching 38.6 months of median overall survival.